GlassScriptPhysician profile
Deborah L Kirby
NPI 1760698146
$10,213.14
in general payments reported to CMS, 2019-2025
58 companies · $2,517 in 2025
The $2,517 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,454 · 2020: $420 · 2021: $585 · 2022: $914 · 2023: $2,283 · 2024: $2,041 · 2025: $2,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,835 · Education: $5.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,834.90 |
| Education | $5.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,518.89 | 2021-2025 | |
| Ucb, INC. | $776.06 | 2019-2025 | Rystiggo, Briviact, Nayzilam |
| Biogen, INC. | $579.58 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Novartis Pharmaceuticals Corporation | $557.86 | 2019-2025 | |
| Argenx US, INC. | $425.24 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $422.38 | 2019-2025 | Mavenclad |
| Genentech USA, INC. | $382.41 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Teva Pharmaceuticals USA, INC. | $374.89 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $355.92 | 2022-2025 | Ingrezza, Ongentys |
| Pfizer INC. | $304.73 | 2019-2025 | |
| Sk Life Science, INC. | $302.02 | 2022-2025 | |
| Lundbeck LLC | $260.25 | 2021-2025 | Vyepti, Rexulti |
| Amgen INC. | $254.71 | 2019-2025 | Uplizna |
| Biohaven Pharmaceutical Holding Company LTD. | $220.15 | 2022 | |
| Amneal Pharmaceuticals LLC | $215.85 | 2021-2025 | Crexont, Rytary, Ongentys |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Kirby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.